Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio Psychedelics Investing
Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials Pharmaceutical Investing
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day Psychedelics Investing
Silo Wellness Adds Biotech Research Expertise to its Psychedelic Wellness Portfolio Psychedelics Investing
Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors Pharmaceutical Investing
Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings Pharmaceutical Investing
Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act Psychedelics Investing
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives Pharmaceutical Investing
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
